India's Bharat Biotech submits data on COVID-19 drug trial in children

1 minute read
Register now for FREE unlimited access to Reuters.com

BENGALURU, Oct 6 (Reuters) - Bharat Biotech said on Wednesday it had submitted data from its COVID-19 vaccine trial in children aged 2 to 18 years to India's drug regulator, becoming the country's first company to have tested its shot in very young children.

The South Asian country is turning its focus towards vaccinating children against the coronavirus, having already administered more than 920 million doses to adults among its population of nearly 1.4 billion.

India's drug regulator last month allowed vaccine maker Serum Institute to enroll kids aged 7 to 11 years for its trial of U.S. drugmaker Novavax's (NVAX.O) COVID-19 vaccine. read more

So far, only drugmaker Zydus Cadila's (CADI.NS) DNA-based COVID-19 vaccine has received emergency use approval in India to be used in adults and children aged atleast 12 years.

Register now for FREE unlimited access to Reuters.com
Reporting by Rama Venkat and Anuron Kumar Mitra in Bengaluru; Editing by Vinay Dwivedi

Our Standards: The Thomson Reuters Trust Principles.